Drug Trial Radar · NCT00489476
Staccato Loxapine in Migraine (in Clinic)
Last checked: Nov 20, 2026Latest source record: Jul 6, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
168
Actual
Start
Jun 2007
Primary completion
Dec 2007
Study completion Dec 2007
Sponsor
- Lead sponsor
- Alexza Pharmaceuticals, Inc.Not stated
- Sponsor type
- Not stated
- First posted
- Jun 21, 2007
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The objective of this trial is to assess the efficacy and safety of Staccato Loxapine in patients with migraine headache with or without aura in a clinical setting.
Conditions
- Migraine
Interventions
Staccato LoxapineDrug
Staccato PlaceboDrug
Placebo aerosol inhalation (0mg)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Pain-relief Response (Pain Severity of NONE or MILD) at 2 HoursTime frame: Baseline and 2 h post-dose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Medvadis
Wellesley Hills, Massachusetts
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.